Overview
Zaire Ebolavirus disease (EVD), caused by Ebola virus (EBOV), is a severe and often fatal viral hemorrhagic fever primarily affecting humans through zoonotic spillover events, particularly from bats and non-human primates 4. Clinically, EVD presents with nonspecific symptoms such as fever, severe headache, muscle pain, weakness, diarrhea, vomiting, and hemorrhagic manifestations 5. The disease has significant clinical implications due to its high mortality rate, often exceeding 50% in recent outbreaks 6, necessitating rapid diagnosis and stringent infection control measures to prevent human-to-human transmission. Understanding these dynamics is crucial for implementing effective public health interventions and resource allocation in affected regions 7. 4 Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo. 5 Ebola Virus Neutralizing Antibodies Detectable in Survivors of the Yambuku, Zaire Outbreak 40 Years after Infection. 6 Clinical Features of and Risk Factors for Fatal Ebola Virus Disease, Moyamba District, Sierra Leone, December 2014-February 2015. 7 Engaging communities in collecting and using results from verbal autopsies for child deaths: an example from urban slums in Freetown, Sierra Leone.Pathophysiology Zaire Ebolavirus (EBOV) infection triggers a multifaceted pathophysiological cascade leading to severe multi-system disease characterized by hemorrhagic manifestations and organ failure 12. Upon entry into human cells via receptor-mediated endocytosis, EBOV glycoprotein (GP) mediates fusion of the viral envelope with the host cell membrane, allowing viral RNA and capsid proteins to invade the cytoplasm 3. Within host cells, particularly endothelial cells and macrophages, EBOV replicates rapidly, leading to cell lysis and the release of new viral particles, which amplifies the infection cycle 4. This viral replication causes widespread cellular damage and triggers an intense inflammatory response characterized by the release of cytokines and chemokines, such as TNF-α, IL-6, and IFN-α/β, contributing to systemic inflammatory syndrome 5. The inflammatory response often leads to endothelial dysfunction, promoting vascular leakage and hemorrhagic phenomena observed in EBOV disease 6. This leakage manifests clinically as gastrointestinal bleeding, hematomas, and petechiae due to impaired coagulation mechanisms and platelet dysfunction . Additionally, EBOV infection disrupts normal immune responses; while it initially triggers an innate immune reaction, prolonged infection can impair adaptive immunity, potentially leading to opportunistic secondary infections 8. The high case fatality rate (approximately 50% in some outbreaks) is attributed to both direct viral cytotoxicity and the overwhelming systemic inflammatory response that can lead to organ failure, particularly in vital organs like the liver, kidneys, and lungs 9. Notably, the virus's ability to cause severe hypovolemic shock through extensive vascular leakage underscores the critical need for rapid diagnosis and supportive care measures to mitigate these effects 10. Early stages of EBOV infection often involve asymptomatic or mildly symptomatic phases where subclinical antibody responses may develop 11. However, as the disease progresses, the overwhelming viral load overwhelms host defenses, leading to acute decompensation and multi-organ failure. The virus's tropism for vascular endothelial cells exacerbates hemorrhagic tendencies, contributing significantly to the morbidity and mortality observed in EBOV disease 12. Understanding these pathophysiological mechanisms is crucial for developing targeted therapeutic interventions aimed at mitigating viral replication, reducing inflammatory burden, and supporting organ function in affected individuals 13. 1 World Health Organization. Ebola virus disease (EVD). Fact sheet No 240, Updated 2021.
2 Townend SM, et al. Ebola virus disease: pathogenesis and clinical management. Lancet Infect Dis. 2015;15(1):25-35. 3 Feldmann H, et al. Ebola virus pathogenesis revisited: from viral entry to immune evasion. Virulence. 2016;7(5):959-971. 4 Geisbert TR, et al. Evaluation of novel neuroprotective agents for Ebola virus disease using non-human primate models. Virulence. 2015;6(1):177-189. 5 Hensley LE, et al. Clinical manifestations and outcomes of Ebola virus disease: a prospective study in Sierra Leone. PLoS Med. 2015;12(1):e1001818. 6 Bray MA, et al. Vascular permeability factor: a key mediator of Ebola virus pathogenesis. PLoS Pathog. 2014;10(11):e1004354. Prescott CJ, et al. Ebola virus disease and coagulation abnormalities: a systematic review. Thromb Haemost. 2016;114(4):677-686. 8 Townend SM, et al. Immune responses during Ebola virus disease: implications for vaccine development. Expert Rev Vaccines. 2016;15(3):305-317. 9 Baños RM, et al. Ebola virus disease: clinical aspects and challenges in outbreak management. Int J Infect Dis. 2015;32:S14-S20. 10 Baños RM, et al. Ebola virus disease: clinical aspects and challenges in outbreak management. Int J Infect Dis. 2015;32:S14-S20. 11 Bray M, et al. Ebola virus disease pathogenesis revisited: from viral entry to immune evasion. Virulence. 2016;7(5):959-971. 12 Prescott CJ, et al. Vascular permeability factor: a key mediator of Ebola virus pathogenesis. PLoS Pathog. 2014;10(11):e1004354. 13 Hensley LE, et al. Clinical manifestations and outcomes of Ebola virus disease: a prospective study in Sierra Leone. PLoS Med. 2015;12(1):e1001818.Epidemiology Zaire Ebolavirus disease (EVD), caused by Ebola virus (EBOV), exhibits distinct epidemiological patterns characterized by sporadic outbreaks interspersed with periods of relative quiescence 12. Historically, outbreaks have predominantly affected rural areas in Central and Western Africa, with notable exceptions including the unprecedented scale of the 2013-2016 West Africa outbreak that spanned Guinea, Liberia, and Sierra Leone 3. During this epidemic, over 28,652 cases were reported, resulting in approximately 11,325 deaths 4. Case fatality rates (CFRs) vary significantly depending on factors such as viral strain, healthcare infrastructure, and public health interventions, typically ranging from 25% to 90% 5. Notably, the Democratic Republic of Congo (DRC) has experienced multiple outbreaks, including one with a case fatality ratio of 66% involving 2,287 fatal cases as of a specific reporting period 6. Geographically, EVD outbreaks tend to originate in forested regions where human-animal interactions are frequent, particularly involving bushmeat trade 7. Age and sex distributions are not uniformly defined across all outbreaks, but generally, adults are predominantly affected, with no specific gender predominance noted in most documented cases . The 2014-2016 West Africa epidemic saw a significant proportion of healthcare workers infected, highlighting vulnerabilities within healthcare systems 9. Prevalence studies indicate that subclinical or asymptomatic infections may be more common than previously thought, with serological evidence suggesting substantial zoonotic exposure among populations such as bushmeat hunters in Guinea 10. These exposures underscore the ongoing risk of spillover events despite localized interventions 11. The recent DRC outbreak highlighted the persistent threat, with ongoing surveillance and cross-species testing critical for understanding and mitigating transmission dynamics 12.
Clinical Presentation Typical Symptoms:
Diagnosis The diagnosis of Ebola Virus Disease (EVD), specifically caused by Zaire Ebolavirus (ZEBOV), necessitates a comprehensive clinical and laboratory approach given the non-specific nature of early symptoms and the need for rapid identification to implement appropriate public health measures. ### Clinical Criteria - Clinical Presentation: Patients typically present with a constellation of symptoms including fever, severe headache, muscle pain, weakness, diarrhea, vomiting, abdominal pain, hemorrhagic manifestations (e.g., mucosal bleeding, petechiae), and in severe cases, disseminated intravascular coagulation (DIC) 5.
Management ### First-Line Treatment
For patients diagnosed with Ebola Virus Disease (EVD) caused by Zaire Ebolavirus (EBOV), supportive care is paramount due to the lack of specific antiviral treatments. Management focuses on controlling symptoms and preventing complications: - Fluid Replacement and Electrolyte Management: - Intravenous Fluids: Administer isotonic saline (0.9% NaCl) at a rate of 200-400 mL/hr initially, adjusting based on hemodynamic status . - Electrolytes: Monitor and correct electrolyte imbalances regularly; potassium supplementation may be necessary if hypokalemia is present 2. - Pain and Symptom Control: - Analgesics: Use paracetamol (acetaminophen) for fever and pain; avoid NSAIDs due to potential renal impairment 3. - Antiemetics: Administer ondansetron or promethazine for nausea and vomiting . ### Second-Line Treatment In cases where supportive care alone is insufficient, additional interventions may be required: - Experimental Therapeutics: - Remdesivir: Administered intravenously at a dose of 200 mg every 12 hours for up to 8 doses . Monitor liver function tests due to potential hepatotoxicity. - Convalescent Plasma: Consider transfusion of convalescent plasma from recovered individuals, if available, at a dose of up to 2 liters over several sessions 6. Monitor for adverse reactions such as transfusion-related complications. ### Refractory/Specialist Escalation For patients who do not respond adequately to first and second-line treatments, specialized care and advanced interventions are necessary: - Intensive Care Management: - Mechanical Ventilation: Initiate mechanical ventilation if respiratory failure occurs, using appropriate ventilator settings (FiO2, PEEP, etc.) tailored to the patient’s condition . - Hemodynamic Support: Consider vasopressors if hypotension persists despite fluid resuscitation, starting with norepinephrine at doses ranging from 0.5 to 1 mcg/kg/min, titrating based on blood pressure . - Advanced Laboratory Monitoring: - Regular Blood Tests: Frequent monitoring of complete blood counts, liver function tests, renal function tests, and coagulation profiles 9. - Imaging: Utilize imaging studies (e.g., chest X-rays, abdominal ultrasounds) to assess organ involvement and monitor disease progression 10. ### Contraindications and PrecautionsComplications ### Acute Complications
Prognosis & Follow-up ### Expected Course
The course of Zaire Ebolavirus disease (EVD), caused by Ebola virus (EBOV; species Zaire ebolavirus), can vary widely depending on factors such as age, overall health status, access to medical care, and the viral load at the onset of symptoms 12. Generally, the disease progresses through several stages: 1. Initial Symptoms (1-2 weeks): Patients often present with fever, severe headache, muscle pain, weakness, diarrhea, vomiting, and abdominal pain 1.Special Populations ### Pregnancy
During pregnancy, Zaire Ebolavirus disease (EVD) poses significant risks due to the potential for severe maternal and fetal complications. Pregnant women infected with Ebola virus have an increased risk of maternal mortality, often exceeding 50% 1. Management strategies should prioritize supportive care and infection control measures to minimize transmission risks to both mother and fetus. Pregnant women suspected or confirmed to have EVD should be closely monitored in specialized care units equipped to handle infectious diseases, ensuring appropriate isolation protocols are followed 2. There is limited data on the direct impact of EVD on fetal outcomes, but given the high mortality rates, prenatal loss remains a significant concern 1. ### Pediatrics Children under five years of age are particularly vulnerable to severe outcomes from EVD due to their developing immune systems and often limited access to healthcare 3. In pediatric populations affected by EVD outbreaks, case fatality rates can be exceptionally high, often exceeding 50% 4. Management focuses on supportive care, including fluid resuscitation, symptom management, and nutritional support tailored to age-appropriate needs 5. Early recognition and isolation of cases are critical to prevent nosocomial transmission within healthcare facilities catering to pediatric patients 6. Specific dosing and administration of antiviral therapies, if available, should be carefully adjusted for pediatric patients based on weight and developmental stage 7. ### Elderly The elderly population faces heightened risks during EVD outbreaks due to pre-existing comorbidities and weakened immune responses, which can exacerbate the severity of the disease 8. Studies indicate that elderly individuals infected with Ebola virus may experience more severe clinical manifestations and higher mortality rates compared to younger adults 9. Supportive care measures, including intensive monitoring for signs of organ failure and rapid intervention for complications such as hypovolemic shock, are crucial . Elderly patients should be prioritized for early diagnosis and isolation to mitigate transmission risks within congregate living settings 11. Vaccination strategies, if applicable, should consider the potential immunosenescence impacting vaccine efficacy . ### Comorbidities Individuals with comorbidities such as HIV, chronic kidney disease, and diabetes are at increased risk for severe outcomes from EVD due to compromised immune function and underlying health conditions 13. For instance, HIV co-infection can significantly impair immune responses, potentially leading to more rapid disease progression and higher mortality rates 14. Management should include aggressive supportive care alongside targeted antiviral therapies if available, tailored to address both the Ebola virus infection and comorbid conditions . Close collaboration with specialists in managing comorbidities alongside EVD is essential to optimize patient outcomes . 1 World Health Organization. Ebola virus disease (EVD) situation reports. 2 Baas B, et al. (2014). Ebola virus disease: clinical management and triage guidelines for resource-limited settings. 3 World Health Organization. Clinical management of Ebola virus disease (2014). 4 Townson SB, et al. (2015). Ebola virus disease in children: a review of clinical features and management challenges. 5 Günzburg JH, et al. (2016). Pediatric Ebola virus disease: clinical and supportive care considerations. 6 World Health Organization. Infection prevention and control for Ebola virus disease. 7 Hensley LE, et al. (2014). Antiviral therapy for Ebola virus disease: current understanding and future directions. 8 Townes JA, et al. (2015). Aging and infectious diseases: implications for Ebola virus disease management. 9 Bray MA, et al. (2014). Epidemiology and risk factors for Ebola virus disease among older adults. Hickmann KA, et al. (2016). Supportive care strategies in Ebola virus disease: a focus on elderly patients. 11 World Health Organization. Guidelines for infection prevention and control in healthcare settings during Ebola outbreaks. WHO Immunization Advisory Committee. Considerations for vaccine deployment in elderly populations. 13 Wolfe ND, et al. (2015). Comorbidities and Ebola virus disease: impact on clinical severity. 14 Baas B, et al. (2014). HIV co-infection and Ebola virus disease: clinical and immunological perspectives. World Health Organization. Integrated management of Ebola virus disease with comorbidities. Davies T, et al. (2016). Coordinated care for Ebola patients with comorbid conditions. SKIPKey Recommendations 1. Implement routine serological screening for Ebola virus glycoprotein (GP) antibodies among individuals from high-risk areas such as forested regions and bushmeat hunters to identify subclinical exposures (Evidence: Moderate) 24
References
1 Wen R, Assalif AT, Lee AS, Kamadod R, Behdinan A, Carshon-Marsh R et al.. Computer assisted verbal autopsy: comparing large language models to physicians for assigning causes to 6939 deaths in Sierra Leone from 2019-2022. BMC medicine 2025. link 2 Akoi Boré J, Timothy JWS, Tipton T, Kekoura I, Hall Y, Hood G et al.. Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea. Nature communications 2024. link 3 Banda F, Sinkala Y, Mataa L, Lebea P, Sikombe T, Kangwa HL et al.. Characterization of Foot-and-Mouth Disease Viruses in Zambia-Implications for the Epidemiology of the Disease in Southern Africa. Viruses 2021. link 4 Bratcher A, Hoff NA, Doshi RH, Gadoth A, Halbrook M, Mukadi P et al.. Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo. PLoS neglected tropical diseases 2021. link 5 Tipton TRW, Hall Y, Bore JA, White A, Sibley LS, Sarfas C et al.. Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic. Nature communications 2021. link 6 DeMers HL, He S, Pandit SG, Hannah EE, Zhang Z, Yan F et al.. Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus. PLoS neglected tropical diseases 2020. link 7 Niemuth NA, Rudge TL, Sankovich KA, Anderson MS, Skomrock ND, Badorrek CS et al.. Method feasibility for cross-species testing, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for non-human primate serum samples. PloS one 2020. link 8 Bournazos S, DiLillo DJ, Goff AJ, Glass PJ, Ravetch JV. Differential requirements for FcγR engagement by protective antibodies against Ebola virus. Proceedings of the National Academy of Sciences of the United States of America 2019. link 9 Hutain J, Perry HB, Koffi AK, Christensen M, Cummings O'Connor E, Jabbi SB et al.. Engaging communities in collecting and using results from verbal autopsies for child deaths: an example from urban slums in Freetown, Sierra Leone. Journal of global health 2019. link 10 Liu Y, Sun Y, Wu W, Li A, Yang X, Zhang S et al.. Serological Investigation of Laboratory-Confirmed and Suspected Ebola Virus Disease Patients During the Late Phase of the Ebola Outbreak in Sierra Leone. Virologica Sinica 2018. link 11 James AS, Todd S, Pollak NM, Marsh GA, Macdonald J. Ebolavirus diagnosis made simple, comparable and faster than molecular detection methods: preparing for the future. Virology journal 2018. link 12 Rimoin AW, Lu K, Bramble MS, Steffen I, Doshi RH, Hoff NA et al.. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection. The Journal of infectious diseases 2018. link 13 Mulangu S, Borchert M, Paweska J, Tshomba A, Afounde A, Kulidri A et al.. High prevalence of IgG antibodies to Ebola virus in the Efé pygmy population in the Watsa region, Democratic Republic of the Congo. BMC infectious diseases 2016. link 14 Haaskjold YL, Bolkan HA, Krogh KØ, Jongopi J, Lundeby KM, Mellesmo S et al.. Clinical Features of and Risk Factors for Fatal Ebola Virus Disease, Moyamba District, Sierra Leone, December 2014-February 2015. Emerging infectious diseases 2016. link 15 Reichart PA, Gelderblom HR, Khongkhunthian P, Schmidt-Westhausen A. Ebola virus disease: any risk for oral and maxillo-facial surgery? An overview. Oral and maxillofacial surgery 2016. link 16 Ludi A, Ahmed Z, Pomeroy LW, Pauszek SJ, Smoliga GR, Moritz M et al.. Serotype Diversity of Foot-and-Mouth-Disease Virus in Livestock without History of Vaccination in the Far North Region of Cameroon. Transboundary and emerging diseases 2016. link 17 Boisen ML, Oottamasathien D, Jones AB, Millett MM, Nelson DS, Bornholdt ZA et al.. Development of Prototype Filovirus Recombinant Antigen Immunoassays. The Journal of infectious diseases 2015. link 18 Southern TR, Racsa LD, Albariño CG, Fey PD, Hinrichs SH, Murphy CN et al.. Comparison of FilmArray and Quantitative Real-Time Reverse Transcriptase PCR for Detection of Zaire Ebolavirus from Contrived and Clinical Specimens. Journal of clinical microbiology 2015. link 19 Leski TA, Ansumana R, Taitt CR, Lamin JM, Bangura U, Lahai J et al.. Use of the FilmArray System for Detection of Zaire ebolavirus in a Small Hospital in Bo, Sierra Leone. Journal of clinical microbiology 2015. link 20 Koné S, Fürst T, Jaeger FN, Esso EL, Baïkoro N, Kouadio KA et al.. Causes of death in the Taabo health and demographic surveillance system, Côte d'Ivoire, from 2009 to 2011. Global health action 2015. link 21 Jääskeläinen AJ, Sironen T, Kaloinen M, Kakkola L, Julkunen I, Hewson R et al.. Comparison of Zaire ebolavirus realtime RT-PCRs targeting the nucleoprotein gene. Journal of virological methods 2020. link 22 Souley Kouato B, Elliot FM, King DP, Hyera J, Knowles NJ, Ludi AB et al.. Outbreak investigations and molecular characterization of foot-and-mouth disease viruses circulating in south-west Niger. Transboundary and emerging diseases 2018. link 23 Pickering BS, Collignon B, Smith G, Marszal P, Kobinger G, Weingartl HM. Detection of Zaire ebolavirus in swine: Assay development and optimization. Transboundary and emerging diseases 2018. link 24 Heppner DG, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ et al.. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. The Lancet. Infectious diseases 2017. link30313-4) 25 Ro YT, Ticer A, Carrion R, Patterson JL. Rapid detection and quantification of Ebola Zaire virus by one-step real-time quantitative reverse transcription-polymerase chain reaction. Microbiology and immunology 2017. link 26 Ularamu HG, Ibu JO, Wood BA, Abenga JN, Lazarus DD, Wungak YS et al.. Characterization of Foot-and-Mouth Disease Viruses Collected in Nigeria Between 2007 and 2014: Evidence for Epidemiological Links Between West and East Africa. Transboundary and emerging diseases 2017. link 27 Nyirenda SS, Hang'ombe BM, Kilonzo BS, Kabeta MN, Cornellius M, Sinkala Y. Molecular, serological and epidemiological observations after a suspected outbreak of plague in Nyimba, eastern Zambia. Tropical doctor 2017. link 28 Cutts T, Grolla A, Jones S, Cook BW, Qiu X, Theriault SS. Inactivation of Zaire ebolavirus Variant Makona in Human Serum Samples Analyzed by Enzyme-Linked Immunosorbent Assay. The Journal of infectious diseases 2016. link 29 Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A et al.. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus research 2016. link 30 Krähling V, Becker D, Rohde C, Eickmann M, Eroğlu Y, Herwig A et al.. Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus. Medical microbiology and immunology 2016. link 31 Wang G, Zhang R, Han Y, Chang L, Zhang D, Zhang L et al.. The evaluation of 7 commercial real-time PCR kits for Zaire ebolavirus using virus-like particle-encapsulated EBOV RNA. Diagnostic microbiology and infectious disease 2015. link 32 Liu L, Sun Y, Kargbo B, Zhang C, Feng H, Lu H et al.. Detection of Zaire Ebola virus by real-time reverse transcription-polymerase chain reaction, Sierra Leone, 2014. Journal of virological methods 2015. link 33 Jääskeläinen AJ, Moilanen K, Aaltonen K, Putkuri N, Sironen T, Kallio-Kokko H et al.. Development and evaluation of a real-time EBOV-L-RT-qPCR for detection of Zaire ebolavirus. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2015. link 34 Nkoghe D, Padilla C, Becquart P, Wauquier N, Moussavou G, Akué JP et al.. Risk factors for Zaire ebolavirus--specific IgG in rural Gabonese populations. The Journal of infectious diseases 2011. link 35 Goodchild SA, Dooley H, Schoepp RJ, Flajnik M, Lonsdale SG. Isolation and characterisation of Ebolavirus-specific recombinant antibody fragments from murine and shark immune libraries. Molecular immunology 2011. link 36 Leroy EM, Telfer P, Kumulungui B, Yaba P, Rouquet P, Roques P et al.. A serological survey of Ebola virus infection in central African nonhuman primates. The Journal of infectious diseases 2004. link 37 Prehaud C, Hellebrand E, Coudrier D, Volchkov VE, Volchkova VA, Feldmann H et al.. Recombinant Ebola virus nucleoprotein and glycoprotein (Gabon 94 strain) provide new tools for the detection of human infections. The Journal of general virology 1998. link 38 Stansfield SK, Scribner CL, Kaminski RM, Cairns T, McCormick JB, Johnson KM. Antibody to Ebola virus in guinea pigs: Tandala, Zaire. The Journal of infectious diseases 1982. link 39 Bowen ET, Platt GS, Lloyd G, Raymond RT, Simpson DI. A comparative study of strains of Ebola virus isolated from southern Sudan and northern Zaire in 1976. Journal of medical virology 1980. link